scan

Reimagine the journey

Discover our pipeline and how we are approaching and developing innovative world-class radiopharmaceutical imaging solutions…

ImaginAb exist to challenge, create and to transform. We align this vision through every aspect of our strategy from development to market authorization and feedback.

Everything we do is focused on reimagining a new world of healthcare potential, optimising the immuno oncology patient care path and delivering greater insight to physicians and comfort to patients.

Our development process is precise and prompt. We partner with global pharmaceutical leaders and world-class clinicians to develop, trial and bring our innovative products to market.

The Sequence of Science

Our approach is targeted and precise. In the diagram below, we show the steps ImaginAb takes to generate an imaging minibody or cys diabody. ImaginAb has developed the ability to rapidly discover and screen new imaging agents. From concept to clinical study, we’re able to complete everything in approximately 18 months following our 3 stage path.

Stage 1

Stage 1

In just 4-6 months, we’re able to achieve from ideal to lead binder.

Stage 2

Stage 2

The binder progresses to lead product. We then add a reporter tag to allow visualization, and validate the product in pre-clinical models.

Stage 3

Stage 3

Safety studies are carried out alongside a clinical grade manufacture, to enable us to undertake a clinical study. This takes approximately 1 year.


The Ideal RPT platform

We believe minibodies and cys dibodies are “the Goldilocks technology of RPT” with the ideal binding affinity, ideal tumor uptake and ideal clearance from the body

Stage 1

Stage 1

In just 4-6 months, we’re able to achieve from ideal to lead binder.

Stage 2

Stage 2

The binder progresses to lead product. We add a therapeutic isotope, and validate the product in pre-clinical models. This enables us to see how the agent reduces tumor growth and whether the distribution of the agent is high in tumors and has the right in vivo characteristics.

Stage 3

Stage 3

Safety studies are carried out alongside a clinical grade manufacture, to enable us to undertake a clinical study. This takes approximately 1 year.


Tomorrow’s cancer treatments begin here…discover our pipeline of biotech innovations.

PET Imaging

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
PET imaging of CD8 Cells in Oncology (89Zr-Df-Crefmirlimab)
 
 
 
 
 
PET imaging CD8 T-cells in Inclusion Body Myositis (89Zr-Df-Crefmirlimab)
 
 
 
 
 
PET Imaging CD8 T-cells trafficking in Oncology and Autoimmune diseases (89Zr-Df-IAB41M2C)
 
 
 
 
 

Optical Imaging

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
PSMA optical imaging: Prostate Cancer (IR800-IAB2MA)
 
 
 
 
 
PSMA optical imaging: Renal Cancer (IR800-IAB2MA)
 
 
 
 
 

Radio Pharmaceutical Therapy (RPT)

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
Prostate Cancer - PSMA (177Lu-DOTA-IAB2MA)
 
 
 
 
 
Solid tumors (undisclosed targets)
 
 
 
 
 

Radbound University to use CD8 ImmunoPET to assess differences in the distribution of CD8+ T-cells of lymphopenia patients

    Not Yet Recruiting
    50+ years
    Male or Female
    NCT04874818

    CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

    Netherlands
    • Radboud University Medical Center
    A subset of patients diagnosed with severe acute respiratory syndrome (SARS)-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced cluster of differentiation (CD)8+ T-cell numbers, is correlated with clinical deterioration and intensive care unit (ICU) admission. The underlying reasons for lymphopenia in coronavirus disease (COVID)-19 is currently unclear, We aim to assess differences in the in vivo distribution of CD8+ T-cells in patients with proven SARS-CoV2 presenting with lymphopenia or with normal lymphocyte counts, using Zirconium-89 ([89Zr])Df-IAB22M2C positron emission tomography (PET) imaging.

Join us to reimagine the future of immuno oncology.